Utama › Mieloma Pelbagai › Missouri › St. Louis
Kajian klinikal Mieloma Pelbagai di St. Louis, MO
24 kajian untuk Mieloma Pelbagai sedang mencari peserta di lokasi dalam dan sekitar St. Louis (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Mengambil pesertaFasa 2
- Washington University School Of Medicine, St Louis
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Mengambil pesertaFasa 1/2
- Washington University School of Medicine, St Louis
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Mengambil pesertaFasa 1
- Research Site, St Louis
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Mengambil pesertaFasa 2
- Washington University School Of Medicine, St Louis
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Mengambil pesertaFasa 4
- Washington University School Of Medicine, St Louis
Collection of Tissue Samples for Cancer Research
Mengambil pesertaKajian pemerhatian
- Washington University - St. Louis, St Louis
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Mengambil pesertaFasa 2
- Washington University School of Medicine, St Louis
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Mengambil pesertaFasa 3
- Washington University School of Medicine, St Louis
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Mengambil pesertaFasa 1/2
- Research Site, St Louis
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Mengambil pesertaFasa 2
- GSK Investigational Site, Bridgeton · 15 mi jauh
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Mengambil pesertaFasa 3
- Mercy Infusion Center - Chippewa, St Louis
- Mercy Hospital South, St Louis
- Missouri Baptist Medical Center, St Louis
- dan 4 lagi
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Mengambil pesertaFasa 3
- Research Site, St Louis
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Mengambil pesertaFasa 2
- Washington University School of Medicine, St Louis
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Mengambil pesertaFasa 2
- Washington University/Siteman Cancer Center, St Louis
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
Mengambil pesertaFasa 1
- Washington University School of Medicine, St Louis
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
Mengambil peserta
- Washington University School of Medicine, St Louis
Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
Mengambil pesertaFasa 1
- Washington University School of Medicine, St Louis
64Cu-LLP2A for Imaging Hematologic Malignancies
Mengambil pesertaFasa awal 1Sukarelawan sihat dialu-alukan
- Washington University School of Medicine, St Louis
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Mengambil pesertaFasa 3
- Saint Louis Cancer and Breast Institute-South City, St Louis
- Mercy Hospital South, St Louis
- Missouri Baptist Medical Center, St Louis
- dan 5 lagi
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
Mengambil pesertaFasa 1
- Washington University School of Medicine, St Louis
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
Mengambil peserta
- Washington University School of Medicine, St Louis
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Mengambil pesertaFasa 1
- Washington University /ID# 266972, St Louis
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
Mengambil pesertaFasa 3
- Saint Louis University, St Louis
Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
Mengambil pesertaFasa 1
- Washington University School of Medicine, St Louis
Kajian Mieloma Pelbagai di bandar lain
- New York City, NY60 kajian
- Boston, MA42 kajian
- Atlanta, GA41 kajian
- Houston, TX38 kajian
- Durham, NC37 kajian
- Nashville, TN32 kajian
- Denver, CO27 kajian
- Rochester, MN24 kajian
- Columbus, OH24 kajian
- Baldwin Park, CA23 kajian
- Chicago, IL22 kajian
- Seattle, WA22 kajian
Kajian lain di St. Louis
- Kanser Paru-paru Bukan Sel Kecil73 kajian
- Kanser Payudara64 kajian
- Kanser Metastatik54 kajian
- Kanser Kolorektal50 kajian
- Kanser Prostat46 kajian
- Kanser (semua jenis)46 kajian
- Kanser Paru-paru39 kajian
- Kanser Ovari38 kajian
- Kanser Pankreas33 kajian
- Kanser Endometrium29 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher28 kajian
- Kegagalan Jantung26 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.